相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Stathmin dynamics modulate the activity of eribulin in breast cancer cells
Mikihiro Yoshie et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)
Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein
Tomohiro Nabekura et al.
BIOCHEMISTRY AND BIOPHYSICS REPORTS (2020)
The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines
Wataru Goto et al.
ANTICANCER RESEARCH (2019)
Uterine leiomyosarcoma well-controlled with eribulin mesylate
Etsuko Fujimoto et al.
INTERNATIONAL CANCER CONFERENCE JOURNAL (2019)
Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
Eisuke Kobayashi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression
Balabhadrapatruni V. S. K. Chakravarthi et al.
MOLECULAR CANCER RESEARCH (2018)
Protein phosphatase 2A as therapeutic targets in various disease models
Rathinasamy Baskaran et al.
LIFE SCIENCES (2018)
Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients
Sayaka Obayashi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin
Fang Shen et al.
ONCOLOGY REPORTS (2017)
Stathmin overexpression is associated with growth, invasion and metastasis of lung adenocarcinoma
Lin Yurong et al.
Oncotarget (2016)
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
Yasuhiro Funahashi et al.
CANCER SCIENCE (2014)
Expression of β-tubulin isotypes in urothelial carcinoma of the bladder
Jung-Woo Choi et al.
WORLD JOURNAL OF UROLOGY (2014)
A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells
Yong Wu et al.
CELLULAR ONCOLOGY (2014)
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies
Joshua J. Oaks et al.
BLOOD (2013)
The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas
Nokitaka Setsu et al.
CANCER (2012)
Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma
Kari J. Brewer Savannah et al.
CLINICAL CANCER RESEARCH (2012)
Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition
Tze Fang Wong et al.
GYNECOLOGIC ONCOLOGY (2011)
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas
Alison M. Karst et al.
GYNECOLOGIC ONCOLOGY (2011)
Possible role of the exchange protein directly activated by cyclic AMP (Epac) in the cyclic AMP-dependent functional differentiation and syncytialization of human placental BeWo cells
Mikihiro Yoshie et al.
HUMAN REPRODUCTION (2010)
Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors
Jannik N. Andersen et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Macromolecular Interaction of Halichondrin B Analogues Eribulin (E7389) and ER-076349 with Tubulin by Analytical Ultracentrifugation
P. Holland Alday et al.
BIOCHEMISTRY (2009)
CIP2A inhibits PP2A in human malignancies
Melissa R. Junttila et al.
CELL (2007)
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas
Eva Hernando et al.
NATURE MEDICINE (2007)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H. Saal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer
DK Price et al.
CANCER INVESTIGATION (2000)
分享论文
